Table 4.

The summary of area under the ROC curve and internal validation

Method	Derivation set	Validation set	Area under curve	95% CI
Internal validation	four trials (completers) four trials (multiple imputation)	four trials four trials	0.698 0.699	0.645 to 0.750 0.649 to 0.750
Leave-one-trial-out cross-validation	Mirtazapine P3 trial, Escitalopram P2 trial, Escitalopram P3 trial	Duloxetine P3 trial	0.655	0.561 to 0.749
	Duloxetine P3 trial, Escitalopram P2 trial, Escitalopram P3 trial	Mirtazapine P3 trial	0.637	0.482 to 0.792
	Duloxetine P3 trial, Mirtazapine P3 trial, Escitalopram P3 trial	Escitalopram P2 trial	0.600	0.469 to 0.733
	Duloxetine P3 trial, Mirtazapine P3 trial, Escitalopram P2 trial	Escitalopram P3 trial	0.541	0.424 to 0.658

ROC, receiver operating characteristic.